within Pharmacolibrary.Drugs.ATC.R;

model R03CC08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.00625,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00275,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03CC08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Procaterol is a short-acting selective beta-2 adrenergic agonist used primarily for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD). It acts as a bronchodilator. Procaterol is not approved for use in the United States or European Union, but is used in Japan and some other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Krogh, N, et al., &amp; Hostrup, M (2016). Pharmacokinetics of nebulized and oral procaterol in asthmatic and non-asthmatic subjects in relation to doping analysis. <i>Drug testing and analysis</i> 8(10) 1056–1064. DOI:<a href=\"https://doi.org/10.1002/dta.1935\">10.1002/dta.1935</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26990656/\">https://pubmed.ncbi.nlm.nih.gov/26990656</a></p></li><li><p>Eldon, MA, et al., &amp; Colburn, WA (1993). Clinical pharmacokinetics and relative bioavailability of oral procaterol. <i>Pharmaceutical research</i> 10(4) 603–605. DOI:<a href=\"https://doi.org/10.1023/a:1018966506819\">10.1023/a:1018966506819</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8483846/\">https://pubmed.ncbi.nlm.nih.gov/8483846</a></p></li><li><p>Kusano, K, et al., &amp; Nagata, S (2016). Pharmacokinetics of procaterol in thoroughbred horses. <i>Journal of veterinary pharmacology and therapeutics</i> 39(3) 264–270. DOI:<a href=\"https://doi.org/10.1111/jvp.12272\">10.1111/jvp.12272</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26538319/\">https://pubmed.ncbi.nlm.nih.gov/26538319</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03CC08;
